Kyowa Kirin International plc.
Michael Bennett has extensive work experience in various roles within the pharmaceutical and biotechnology industry. Michael is currently serving as the VP Corporate Liaison at Kyowa Kirin International plc., where they work on regional and global projects, focusing on the expansion of rare disease products into different territories and collaborating with the Japanese headquarters on licensing pharmaceutical assets.
Prior to this, Michael was the Director of Business Development at The Cell and Gene Therapy Catapult, responsible for worldwide business development and commercial negotiations. Michael also worked as the Director/Owner of Peapod Consulting Limited, providing marketing solutions and advising on integrated marketing campaigns and intellectual property strategies.
Earlier in their career, Michael held positions such as Vice President of Business Development and Licensing at Oxford Gene Technology, VP of Sales and Marketing at Molecular Sensing plc, and Market Manager at Roche Diagnostics. Michael also worked as an International Product Manager at Hybaid Ltd.
Michael started their career as a Post Doctoral Research Associate at the University of Bristol and the Royal Free Hospital London. Overall, they have a diverse background in business development, marketing, intellectual property, and research within the pharmaceutical and biotechnology sectors.
Michael Bennett obtained a BSc in Biology from the University of the West of Scotland from 1985 to 1989. Michael then pursued a D.Phil at the University of Oxford from 1989 to 1992, focusing on Gene Expression in the Gonads of Normal and Mutant Rodents.
This person is not in any offices
Kyowa Kirin International plc.
At Kyowa Kirin International (KKI), commitment to life is at our core. We strive to answer the unmet medical needs of patients, their families, and the medical professionals who care for them. With more than 700 people focused on this purpose, we are a rapidly growing specialty biopharmaceutical company, engaged in the development and commercialisation of innovative medicines in the therapy areas of oncology, nephrology and central nervous system (CNS) across Europe and the Middle East. KKI, headquartered in Marlow, England, and Galashiels, Scotland, is owned by Kyowa Kirin Co., Ltd (KKC), of Japan. Founded in 1949, KKC has a successful track record in Japan and has expanded globally. Our history of innovation is built on a strong legacy of scientific discovery and fostering collaborations that accelerate the delivery of innovative medicines to patients. Grounded in our expertise in antibody engineering, we continue to investigate new molecules with the potential to contribute to the future of healthcare and make a difference in the lives of patients. At KKI, it is our people who have helped make a real difference to our success. Working together, our employees excel in achieving results quickly and effectively, bringing diverse and unique viewpoints to the company to achieve our vision. Our passion and energy around our core values of commitment to life, innovation, integrity and teamwork help ensure that every day, each of us is focused on not just making medicines, but also making people smile. With our strong legacy and exciting future, KKI is looking for great people to join our team and support our commitment to life.